WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today the completion of its previously reported public offering of 5,750,000 shares of common stock. The Company received net proceeds, after underwriting discounts and commissions and estimated expenses, of approximately $38.0 million.
